Published in Clin Res Hepatol Gastroenterol on December 27, 2012
Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol (2014) 1.05
Garcinia Cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation. World J Gastroenterol (2013) 0.88
Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. World J Gastroenterol (2014) 0.87
Translational approaches: from fatty liver to non-alcoholic steatohepatitis. World J Gastroenterol (2014) 0.87
Physical activity assessment in patients with axial spondyloarthritis compared to healthy controls: a technology-based approach. PLoS One (2014) 0.82
Nutritional status evaluation in patients affected by bethlem myopathy and ullrich congenital muscular dystrophy. Front Aging Neurosci (2014) 0.78
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease. Hepat Med (2013) 0.77
Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol (2015) 0.76
Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial. Nutr J (2013) 0.76
Nonmedicinal interventions in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol (2015) 0.75
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005) 5.11
The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol (2006) 3.62
A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol (2010) 3.53
Epidemiology of non-alcoholic fatty liver disease. Dig Dis (2010) 3.44
Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol (2009) 2.75
Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol (2009) 2.09
Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis (2008) 2.06
'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol (2006) 2.03
Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology (2004) 2.02
Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis (2012) 1.79
Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol (2010) 1.76
From NAFLD in clinical practice to answers from guidelines. J Hepatol (2013) 1.76
ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population. Dig Liver Dis (2012) 1.62
A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol (2010) 1.38
Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci (2003) 1.37
Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project). World J Gastroenterol (2008) 1.31
Emx2 regulates the proliferation of stem cells of the adult mammalian central nervous system. Development (2002) 1.24
Fatty liver: how frequent is it and why? Ann Hepatol (2004) 1.24
Genes and translocations involved in POF. Am J Med Genet (2002) 1.23
Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol (2005) 1.16
A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica (2008) 1.16
Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int (2012) 1.11
Liver and diabetes. A vicious circle. Hepatol Res (2013) 1.10
Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol (2005) 1.10
Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol (2015) 1.08
Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology (2007) 1.08
Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B. J Biol Chem (2009) 1.07
Mouse ovary developmental RNA and protein markers from gene expression profiling. Dev Biol (2005) 1.05
Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des (2013) 1.04
Fatty liver, carotid disease and gallstones: a study of age-related associations. World J Gastroenterol (2006) 1.03
Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol (2009) 1.02
Scapula development is governed by genetic interactions of Pbx1 with its family members and with Emx2 via their cooperative control of Alx1. Development (2010) 1.02
Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol (2012) 1.00
Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond) (2008) 0.98
Statins in liver disease: a molehill, an iceberg, or neither? Hepatology (2008) 0.96
Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? Intern Emerg Med (2011) 0.95
Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology (2006) 0.95
Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol (2011) 0.92
Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. J Hepatol (2012) 0.92
Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother (2011) 0.90
Gender, fatty liver and GGT. Hepatology (2006) 0.89
Hepatitis C and diabetes: the inevitable coincidence? Expert Rev Anti Infect Ther (2009) 0.89
Physical activity for the prevention and treatment of metabolic disorders. Intern Emerg Med (2013) 0.89
Should nonalcoholic fatty liver disease be renamed? Dig Dis (2005) 0.89
Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol (2011) 0.89
Measured physical activity in anorexia nervosa: features and treatment outcome. Int J Eat Disord (2013) 0.88
Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver Int (2010) 0.86
Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can J Gastroenterol (2009) 0.86
Magnetic resonance for quantitative assessment of liver steatosis: a new potential tool to monitor antiretroviral-drug-related toxicities. Antivir Ther (2012) 0.86
Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption. Hepatology (2003) 0.85
Dysmetabolic changes associated with HCV: a distinct syndrome? Intern Emerg Med (2008) 0.84
Low adherence of a clinically healthy Italian population to nutritional recommendations for primary prevention of chronic diseases. Nutr Metab Cardiovasc Dis (2006) 0.84
Genotype/phenotype correlations of males affected by Simpson-Golabi-Behmel syndrome with GPC3 gene mutations: patient report and review of the literature. J Pediatr Endocrinol Metab (2003) 0.84
Body composition, eating disorder psychopathology, and psychological distress in anorexia nervosa: a longitudinal study. Am J Clin Nutr (2014) 0.84
Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Am J Gastroenterol (2008) 0.84
The hepatitis C virus-associated dysmetabolic syndrome. Hepatology (2008) 0.84
Metabolic syndrome: a child is not a small adult. Int J Pediatr Obes (2008) 0.83
Relationship of serum fetuin-A levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography. Metab Syndr Relat Disord (2013) 0.83
Growth hormone plasma levels in nonalcoholic fatty liver disease. Am J Gastroenterol (2002) 0.83
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol (2014) 0.83
Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res (2011) 0.82
Fertility and pregnancy in women affected by glycogen storage disease type I, results of a multicenter Italian study. J Inherit Metab Dis (2012) 0.81
Nonalcoholic fatty liver disease induced by leuprorelin acetate. J Clin Gastroenterol (2008) 0.81
The management of patients with new onset of upper gastro-intestinal symptoms in primary care. Dig Liver Dis (2010) 0.81
Quality of life in adult patients with glycogen storage disease type I: results of a multicenter italian study. JIMD Rep (2013) 0.80
Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease. Dig Liver Dis (2012) 0.80
Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease. Arch Med Res (2012) 0.80
Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia? Intern Emerg Med (2008) 0.79
Comparative cytotoxic and cytoprotective effects of taurohyodeoxycholic acid (THDCA) and tauroursodeoxycholic acid (TUDCA) in HepG2 cell line. Biochim Biophys Acta (2002) 0.79
Developmental overfeeding alters hypothalamic neuropeptide mRNA levels and response to a high-fat diet in adult mice. Peptides (2011) 0.79
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 0.79
Comparison between dual-energy X-ray absorptiometry and skinfolds thickness in assessing body fat in anorexia nervosa before and after weight restoration. Clin Nutr (2012) 0.78
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients. Steroids (2008) 0.78
Statins and HCV: a complex issue. Hepatology (2007) 0.78
Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. Hepatol Res (2012) 0.78
If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis? Dig Liver Dis (2012) 0.78
Influence of lifestyle habits, nutritional status and insulin resistance in NAFLD. Front Biosci (Elite Ed) (2012) 0.78